ArticleMikrochimica acta2025
Early diagnosis of Parkinson's disease using split aptamer-based lateral flow assay with saliva sample.
Article in Mikrochimica acta, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Parkinson's disease (PD), the second most common neurodegenerative disorder, is typically diagnosed based on clinical observation of motor symptoms such as resting tremor, rigidity, and bradykinesia. This underscores the urgent need for a diagnostic tool capable of detecting PD at an earlier stage. Since the appearance of α-synuclein oligomer in saliva occurs earlier than the onset of motor symptoms, we introduce a lateral flow strip utilizing split aptamer to detect α-synuclein oligomer in the saliva of PD patients. When α-synuclein oligomer are present, they facilitate the reassembly of split aptamer, creating an "aptamer-α-synuclein oligomer-aptamer" sandwich structure. This assembly allows DNA-modified gold nanoparticles to be captured on the test line of the strip, producing a visible red band. Through careful optimization of the strip's operational conditions, this system exhibited a linear relationship within the range 0-10 µmol/L and a LOD of 62.72 nmol/L. Quantitative analysis of the results from PD patients showed positive outcomes in 14 out of 20 cases. Compared to existing detection methods, this approach offers several advantages, including visual results, short detection time, ease of use, low cost, portability and no requirement for complex sample pretreatment. These features make it a promising tool for the early diagnosis and visual assessment of PD.
Indexed as
Identifiers
41212423What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.